Hims and Hers Health Inc vs Progressive Corp — how do they compare? Hims and Hers Health Inc trades at $28.41 (market cap $6.89B), while Progressive Corp trades at $218.73 (market cap $124.28B). The key difference: Progressive Corp is far larger — about 18× Hims and Hers Health Inc's market cap, and Progressive Corp pays a 0.19% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Progressive Corp for 81 Days on average.
| HIMS | PGR | |
|---|---|---|
Market Cap | $6.89B | $124.28B |
Volume | 5,446,628 | 2,551,191 |
Sector | Health | Financials |
52-Week High | $62.76 | $242.16 |
52-Week Low | $14.52 | $190.40 |
Typical Hold Time | 21 Days | 81 Days |
Enterprise Value | $7.60B | $132.48B |
Dividend Yield | — | 0.19% |
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up 0.24% on the day, with a bullish technical signal from moving averages but mixed earnings performance. Revenue grew to $2.35 billion in 2025, yet the company posted a net loss of $142 million in 2026, reflecting profitability challenges. High valuation ratios like a P/E of 57.14 and negative ROE of -32.03% indicate premium pricing despite weak earnings. Recent news highlights multiple securities class action lawsuits filed in October 2026, creating legal overhangs.
The stock faces headwinds from profitability struggles and legal risks, but analyst consensus remains a Buy with a $32.17 price target, suggesting modest upside. Investment appeal hinges on resolving operational inefficiencies and legal issues to align valuation with fundamentals, while current sentiment is cautious due to recent earnings misses and regulatory scrutiny.
PGR trades at $218.73, up 3.15% today, with a bullish technical signal from moving averages and strong fundamentals including a 12.85% net income margin and 34.94% ROE. Revenue grew from $49.6B in 2022 to $87.6B in 2025, with net income surging to $11.3B. The company recently announced a $0.10 dividend payable in October 2026, and Q2 2026 earnings beat expectations.
The outlook is positive given robust earnings growth and analyst consensus price target of $222.23, though risks include intensifying competition in personal auto insurance and potential market volatility. Institutional interest remains strong with recent position increases by funds like QRG Capital Management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →